Recent Updates
Recently added Catalysts
XLO Positive Sentiment

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Wednesday, February 28, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xilio Therapeutics, a biotechnology company focused on immuno-oncology therapies, announced its participation in the TD Cowen 44th Annual Health Care Conference. CEO Renée Russo will join a panel discussion titled 'Novel Immuno-Oncology' on March 4, 2024. Attendees can access a live webcast of the event through the company's website, which will also host a replay for 30 days afterward. This engagement illustrates Xilio's commitment to advancing cancer treatment discussions.
Price reaction · baseline $8.75 (2024-02-27 close) · hit after-hours · clean, no other XLO news in the window
day 0 close
+5.6%
day 1
+13.4%
day 3 · peak
+16.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Xilio Therapeutics is participating in a prestigious health care conference.
  • The panel discussion focuses on novel immuno-oncology, highlighting the company's innovative approach.
  • CEO Renée Russo's presence indicates the importance of the event for stakeholder engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+66%
120-day peak, hindsight
Typical move
21.2%
average across 4 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
XTX501
Phase 1 · Metastatic NSCLC - Non-Small Cell Lung Cancer

Full Press Release Details

WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in the “Novel Immuno-Oncology” panel discussion during the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 10:30 am EST.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Investors: Melissa Forst Argot Partners Xilio@argotpartners.com Media: Dan Budwick 1AB dan@1abmedia.com

Frequently Asked Questions

What is Xilio Therapeutics focused on?

Xilio Therapeutics develops tumor-activated immuno-oncology therapies for cancer.

When will the panel discussion take place?

The panel discussion is on March 4, 2024, at 10:30 am EST.

How can I access the live webcast?

The live webcast can be found under 'Events & Presentations' on Xilio's website.

Will the webcast be available after the event?

Yes, a replay will be available for 30 days after the presentation.

Who is the CEO of Xilio Therapeutics?

René Russo, Pharm.D. is the president and CEO of Xilio Therapeutics.

ShareAdd on Google
Tags: XLO Viatris Investor Conferences Healthcare Xilio Therapeutics immuno-oncology TD Cowen health care conference Renée Russo
Last updated: Feb 28, 2024

Biotech snapshot

Cash runway
$136M liquidity · $6M/mo burn
~22 mo
Low dilution risk
Lead asset
XTX501Phase 1
Metastatic NSCLC - Non-Small Cell Lung Cancer →

Catalyst track record

+66%
best trade around XLO's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for XLO.

See every catalyst's timing & PoA →